Skip to main content
Skip to footer
Opens in a new tab
About
Our Philosophy
Meet Our Care Team
Your Care Experience
Services
Cancer Care
Laboratory Services
Same-Day CT Imaging
Liberty Pharmacy
Infusion Services
Clinical Trials
Is a Clinical Trial Right for Me?
Find a Clinical Trial
Frequently Asked Questions
About PhaseWell Research
Resources
Patient Resources
Patient Forms
Billing & Insurance
Educational Resources
Approved Oncology Drugs (PDF)
Referring Physicians
Contact Us
About
Our Philosophy
Meet Our Care Team
Your Care Experience
Services
Cancer Care
Laboratory Services
Same-Day CT Imaging
Liberty Pharmacy
Infusion Services
Clinical Trials
Is a Clinical Trial Right for Me?
Find a Clinical Trial
Frequently Asked Questions
About PhaseWell Research
Resources
Patient Resources
Patient Forms
Billing & Insurance
Educational Resources
Approved Oncology Drugs (PDF)
Referring Physicians
Contact Us
Category:
Solid Tumors
A First-In-Human Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Locally Advanced or Metastatic Solid Tumors including NSCLC with MET Alterations
September 11, 2026
A Phase 1/2a, Open-Label Study of SA53-OS, an MDM2 Inhibitor, in Locally Advanced or Metastatic p53 Wild-Type Solid Tumors
September 11, 2026
A Phase 1/2a, Multicenter, Open-Label, First-in-Human Study of DB-1311 in Advanced/Metastatic Solid Tumors
September 11, 2026
An Open-Label, Multicenter, Multi-Arm Phase 1 Study of ADU-1805 in Adults with Advanced Solid Tumors
September 11, 2026
A Phase 1/2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Advanced Cancer
September 11, 2026
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Advanced Solid Tumors
September 11, 2026
A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study of Topical HT-001 for Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitor
September 11, 2026
A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation Study of Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory Small Cell Lung Cancer
September 11, 2026
A Phase 1/2a, Multicenter, Open-Label, First-in-Human Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
September 11, 2026
A Phase 1, Open-Label, Multicenter Study of the Pharmacokinetics and Safety of Pralatrexate in Advanced Solid Tumor or Hematological Malignancy with Normal or Mild/Moderate/Severe Hepatic Impairment
September 11, 2026
